A
Andrea Fülöp
Publications - 23
Citations - 11729
Andrea Fülöp is an academic researcher. The author has contributed to research in topics: Pembrolizumab & Lung cancer. The author has an hindex of 16, co-authored 21 publications receiving 8051 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Alexander Luft,David Vicente,Ali Tafreshi,Mahmut Gumus,Julien Mazieres,Barbara Hermes,Filiz Çay Şenler,Tibor Csőszi,Andrea Fülöp,Jerónimo Rodríguez-Cid,Jonathan Wilson,Shunichi Sugawara,Terufumi Kato,Ki Hyeong Lee,Ying Cheng,Silvia Novello,Balazs Halmos,Xiaodong Li,Gregory M. Lubiniecki,Bilal Piperdi,Dariusz M. Kowalski,Keynote Investigators +22 more
TL;DR: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus pac litaxel or nab‐paclitaxel resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csoszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Kristel Vandormael,Antonio Riccio,J. Yang,M. Catherine Pietanza,Julie R. Brahmer +17 more
TL;DR: With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations, despite crossover from the control arm to pembrolezumab as subsequent therapy.
Journal ArticleDOI
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Ticiana A. Leal,Jonathan W. Riess,Erin Jensen,Bin Zhao,M. Catherine Pietanza,Julie R. Brahmer +18 more
TL;DR: The first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC) was reported in this article.
Journal ArticleDOI
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Jonathan W. Goldman,Mikhail Dvorkin,Y. Chen,Niels Reinmuth,Katsuyuki Hotta,D. Trukhin,Galina Statsenko,Maximilian J Hochmair,Mustafa Ozguroglu,J.H. Ji,Marina Chiara Garassino,Oleksandr Voitko,A. Poltoratskiy,Santiago Ponce,Francesco Verderame,Libor Havel,Igor Bondarenko,Andrzej Kazarnowicz,György Losonczy,Nikolay Conev,Jon Armstrong,N. Byrne,P. Thiyagarajah,Haiyi Jiang,Luis Paz-Ares,Nataliia Voitko,Nikolay Conev,Maximilian Hochmair,Otto C. Burghuber,Irfan Cicin,Vladimir Moiseenko,Mustafa Erman,Dariusz M. Kowalski,Marek Z. Wojtukiewicz,Hryhoriy Adamchuk,Alexander Vasilyev,Serhii Shevnia,Spartak Valev,Maria Amelia Insa Molla,Grygorii Ursol,Anne Chiang,Sylvia Hartl,Zsolt Horváth,Gábor Pajkos,Sang-We Kim,Alexey Smolin,Tuncay Göksel,Shaker R. Dakhil,Jaromir Roubec,Krisztina Bogos,Robin Cornelissen,Jongmin Lee,Maria Rosario Garcia Campelo,Marta Lopez Brea,Ahmet Alacacioglu,Ignacio Casarini,Rumyana Ilieva,Ivan Tonev,Attila Somfay,Jair Bar,Alona Zer Kuch,Mauro Minelli,Roberta Bartolucci,F. Roila,Haruhiro Saito,Koichi Azuma,Gyeong-Won Lee,Alexander Luft,Michal Urda,Juan Ignacio Delgado Mingorance,Margarita Majem Tarruella,David R. Spigel,Krassimir Koynov,Milada Zemanova,Jens Panse,Christian Schulz,Zsolt Pápai Székely,Veronika Sárosi,Angelo Delmonte,Anna Cecilia Bettini,Makoto Nishio,Isamu Okamoto,Lizza Hendriks,Slawomir Mandziuk,Yun Gyoo Lee,Lyubov Vladimirova,Dolores Isla Casado,Manuel Domine Gomez,Alejandro Navarro Mendivil,Teresa Morán Bueno,Shang-Yin Wu,Jeanna Knoble,Jana Skrickova,Violetka Venkova,Werner Hilgers,E. Laack,Helge Bischoff,Andrea Fülöp,Ibolya Laczó,Judit Kósa,Andras Telekes,Tatsuya Yoshida,Shintaro Kanda,Toyoaki Hida,Hidetoshi Hayashi,Tadashi Maeda,Tetsuji Kawamura,Yasuharu Nakahara,Niels Claessens,Ki Hyeong Lee,Chao-Hua Chiu,Sheng-Hao Lin,Chien-Te Li,Ahmet Demirkazik,Eric Schaefer,Petros Nikolinakos,Jeffrey Schneider,Sunil Babu,Bernd Lamprecht,Michael Studnicka,Carlos Fausto Nino Gorini,Juraj Kultan,Vitezslav Kolek,Pierre-Jean Souquet,Denis Moro-Sibilot,Maya Gottfried,Egbert F. Smit,Kyung Hee Lee,Peter Kasan,Jozef Chovanec,Olexandr Goloborodko,Oleksii Kolesnik,Yuriy Ostapenko,Shailendra Lakhanpal,Basir Haque,Winston Chua,Joseph Stilwill,Susana Noemi Sena,Gustavo Girotto,Pedro Rafael Martins De Marchi,Fabricio Augusto Martinelli de Oliveira,Pedro Dos Reis,Rositsa Krasteva,Yanqiu Zhao,Chengshui Chen,Leona Koubkova,Gilles Robinet,Christos Chouaid,Christian Grohe,Jürgen Alt,Eszter Csánky,Éva Somogyiné Ezer,Norman Isaac Heching,Young Hak Kim,Shinji Aatagi,Shoichi Kuyama,Daijiro Harada,Naoyuki Nogami,Hiroshi Nokihara,Hisatsugu Goto,Agnes Staal van den Brekel,Eun Kyung Cho,Joo Hang Kim,Doina Ganea,Tudor Ciuleanu,Ekaterina Popova,Dina Sakaeva,Marian Stresko,Pavol Demo,Robert Godal,Yu-Feng Wei,Yen-Hsun Chen,Te Chun Hsia,Kang-Yun Lee,Huang-Chih Chang,Chin-Chou Wang,Afshin Dowlati,Christopher Sumey,Steven Francis Powell,Jonathan H. Goldman,J. J. Zarba,Emilio Batagelj,Andrea Viviana Pastor,Mauro Zukin,Clarissa Serodio da Rocha Baldotto,Luis Alberto Schlittler,Aknar Calabrich,Claudia Sette,Asen Dudov,Caicun Zhou,Hervé Lena,Susanne Lang,Zsuzsanna Papai,Koichi Goto,Shigeki Umemura,Kenya Kanazawa,Yu Hara,Masahiro Shinoda,Masahiro Morise,Jeroen Hiltermann,Robert Mróz,Andrei Ungureanu,Igor Andrasina,Gee-Chen Chang,Ihor Vynnychenko,Yaroslav Shparyk,Anna Kryzhanivska,Helen Ross,Kailhong Mi,Rodney Jamil,M. Williamson,Joseph Spahr,Zhigang Han,Mengzhao Wang,Zhixiong Yang,Jie Hu,Wei Li,Jun Zhao,Jifeng Feng,Shenglin Ma,Xiangdong Zhou,Zongan Liang,Yi Hu,Yuan Chen,Minghong Bi,Yongqian Shu,Kejun Nan,Jianying Zhou,Wei Zhang,Rui Ma,Nong Yang,Zhong Lin,Gang Wu,Jian Fang,Helong Zhang,Kai Wang,Zhendong Chen +236 more
Abstract: Summary Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus platinum–etoposide alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum–etoposide versus platinum–etoposide alone. Methods CASPIAN is an ongoing, open-label, sponsor-blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 countries worldwide. Eligible patients were aged 18 years or older (20 years in Japan) and had treatment-naive, histologically or cytologically documented ES-SCLC, with a WHO performance status of 0 or 1. Patients were randomly assigned (1:1:1) in blocks of six, stratified by planned platinum, using an interactive voice-response or web-response system to receive intravenous durvalumab plus tremelimumab plus platinum–etoposide, durvalumab plus platinum–etoposide, or platinum–etoposide alone. In all groups, patients received etoposide 80–100 mg/m2 on days 1–3 of each cycle with investigator's choice of either carboplatin area under the curve 5–6 mg/mL/min or cisplatin 75–80 mg/m2 on day 1 of each cycle. Patients in the platinum–etoposide group received up to six cycles of platinum–etoposide every 3 weeks and optional prophylactic cranial irradiation (investigator's discretion). Patients in the immunotherapy groups received four cycles of platinum–etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks. The two primary endpoints were overall survival for durvalumab plus platinum–etoposide versus platinum–etoposide and for durvalumab plus tremelimumab plus platinum–etoposide versus platinum–etoposide in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered at ClinicalTrials.gov, NCT03043872. Findings Between March 27, 2017, and May 29, 2018, 972 patients were screened and 805 were randomly assigned (268 to durvalumab plus tremelimumab plus platinum–etoposide, 268 to durvalumab plus platinum–etoposide, and 269 to platinum–etoposide). As of Jan 27, 2020, the median follow-up was 25·1 months (IQR 22·3–27·9). Durvalumab plus tremelimumab plus platinum–etoposide was not associated with a significant improvement in overall survival versus platinum–etoposide (hazard ratio [HR] 0·82 [95% CI 0·68–1·00]; p=0·045); median overall survival was 10·4 months (95% CI 9·6–12·0) versus 10·5 months (9·3–11·2). Durvalumab plus platinum–etoposide showed sustained improvement in overall survival versus platinum–etoposide (HR 0·75 [95% CI 0·62–0·91]; nominal p=0·0032); median overall survival was 12·9 months (95% CI 11·3–14·7) versus 10·5 months (9·3–11·2). The most common any-cause grade 3 or worse adverse events were neutropenia (85 [32%] of 266 patients in the durvalumab plus tremelimumab plus platinum–etoposide group, 64 [24%] of 265 patients in the durvalumab plus platinum–etoposide group, and 88 [33%] of 266 patients in the platinum–etoposide group) and anaemia (34 [13%], 24 [9%], and 48 [18%]). Any-cause serious adverse events were reported in 121 (45%) patients in the durvalumab plus tremelimumab plus platinum–etoposide group, 85 (32%) in the durvalumab plus platinum–etoposide group, and 97 (36%) in the platinum–etoposide group. Treatment-related deaths occurred in 12 (5%) patients in the durvalumab plus tremelimumab plus platinum–etoposide group (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enterocolitis, general physical health deterioration and multiple organ dysfunction syndrome, pneumonia, pneumonitis and hepatitis, respiratory failure, and sudden death [n=1 each]), six (2%) patients in the durvalumab plus platinum–etoposide group (cardiac arrest, dehydration, hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1 each]), and two (1%) in the platinum–etoposide group (pancytopenia and thrombocytopenia [n=1 each]). Interpretation First-line durvalumab plus platinum–etoposide showed sustained overall survival improvement versus platinum–etoposide but the addition of tremelimumab to durvalumab plus platinum–etoposide did not significantly improve outcomes versus platinum–etoposide. These results support the use of durvalumab plus platinum–etoposide as a new standard of care for the first-line treatment of ES-SCLC. Funding AstraZeneca.